41 related articles for article (PubMed ID: 8365505)
1. Stratification of ovarian cancer borderline from high-grade serous carcinoma patients by quantitative serum NMR spectroscopy of metabolites, lipoproteins, and inflammatory markers.
Bae G; Berezhnoy G; Koch A; Cannet C; Schäfer H; Kommoss S; Brucker S; Beziere N; Trautwein C
Front Mol Biosci; 2023; 10():1158330. PubMed ID: 37168255
[No Abstract] [Full Text] [Related]
2. High Serum Carbohydrate Antigen (CA) 125 Level Is Associated With Poor Prognosis in Patients With Light-Chain Cardiac Amyloidosis.
Li M; Wu Z; Tudahun I; Liu N; Lin Q; Liu J; Wang Y; Chen M; Chen Y; Qi N; Zhu Q; Li J; Li W; Tang J; Liu Q
Front Cardiovasc Med; 2021; 8():692083. PubMed ID: 34778387
[No Abstract] [Full Text] [Related]
3. Preoperative serum levels of cancer antigen 125 and carcinoembryonic antigen ratio can improve differentiation between mucinous ovarian carcinoma and other epithelial ovarian carcinomas.
Choi JH; Sohn GS; Chay DB; Cho HB; Kim JH
Obstet Gynecol Sci; 2018 May; 61(3):344-351. PubMed ID: 29780776
[TBL] [Abstract][Full Text] [Related]
4. Nanoparticle Probes for the Detection of Cancer Biomarkers, Cells, and Tissues by Fluorescence.
Chinen AB; Guan CM; Ferrer JR; Barnaby SN; Merkel TJ; Mirkin CA
Chem Rev; 2015 Oct; 115(19):10530-74. PubMed ID: 26313138
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of CA125 and NT-proBNP values in patients undergoing transcatheter aortic valve implantation.
Ayhan H; Kasapkara HA; Durmaz T; Keleş T; Sarı C; Baştuğ S; Erdoğan KE; Bayram NA; Bilen E; Akçay M; Bozkurt E
J Geriatr Cardiol; 2015 Mar; 12(2):100-6. PubMed ID: 25870611
[TBL] [Abstract][Full Text] [Related]
6. Higher carbohydrate antigen 125 levels are associated with increased risk of coronary heart disease in elderly chinese: a population-based case-control study.
Li X; He M; Zhu J; Yao P; Li X; Yuan J; Min X; Lang M; Yang H; Hu FB; Wu T; Wei S
PLoS One; 2013; 8(11):e81328. PubMed ID: 24303042
[TBL] [Abstract][Full Text] [Related]
7. CA125 in ovarian cancer.
Scholler N; Urban N
Biomark Med; 2007 Dec; 1(4):513-23. PubMed ID: 20477371
[TBL] [Abstract][Full Text] [Related]
8. Factors associated with the development of atrial fibrillation in patients with rheumatic mitral stenosis.
Ozaydin M; Turker Y; Varol E; Alaca S; Erdogan D; Yilmaz N; Dogan A
Int J Cardiovasc Imaging; 2010 Jun; 26(5):547-52. PubMed ID: 20333471
[TBL] [Abstract][Full Text] [Related]
9. Elevated carbohydrate antigen 125 levels in hypertrophic cardiomyopathy patients with heart failure.
Varol E; Ozaydin M; Altinbas A; Aslan SM; Dogan A; Dede O
Heart Vessels; 2007 Jan; 22(1):30-3. PubMed ID: 17285443
[TBL] [Abstract][Full Text] [Related]
10. Development of a CA125-mesothelin cell adhesion assay as a screening tool for biologics discovery.
Scholler N; Garvik B; Hayden-Ledbetter M; Kline T; Urban N
Cancer Lett; 2007 Mar; 247(1):130-6. PubMed ID: 16677756
[TBL] [Abstract][Full Text] [Related]
11. Bead-based ELISA for validation of ovarian cancer early detection markers.
Scholler N; Crawford M; Sato A; Drescher CW; O'Briant KC; Kiviat N; Anderson GL; Urban N
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2117-24. PubMed ID: 16609024
[TBL] [Abstract][Full Text] [Related]
12. Do CA125 response criteria overestimate tumour response in second-line treatment of epithelial ovarian carcinoma?
Gronlund B; Hansen HH; Høgdall C; Høgdall EV; Engelholm SA
Br J Cancer; 2004 Jan; 90(2):377-82. PubMed ID: 14735180
[TBL] [Abstract][Full Text] [Related]
13. The roles of second-look laparotomy and cancer antigen 125 in the management of ovarian carcinoma.
Selman AE; Copeland LJ
Curr Oncol Rep; 1999 Sep; 1(1):71-6. PubMed ID: 11122801
[TBL] [Abstract][Full Text] [Related]
14. CA 125 in gynecological pathology--a review.
Kenemans P; Yedema CA; Bon GG; von Mensdorff-Pouilly S
Eur J Obstet Gynecol Reprod Biol; 1993 Apr; 49(1-2):115-24. PubMed ID: 8365505
[TBL] [Abstract][Full Text] [Related]
15. Tumor marker CA 125 in diagnosis, monitoring management and follow-up of patients with ovarian tumors.
Vinokurov VL; Dudarev AL; Jurkova LE; Lapchenkov VI; Barbanel EJ
Eur J Gynaecol Oncol; 1992; 13(2):205-8. PubMed ID: 1587297
[TBL] [Abstract][Full Text] [Related]
16. OVX1 radioimmunoassay complements CA-125 for predicting the presence of residual ovarian carcinoma at second-look surgical surveillance procedures.
Xu FJ; Yu YH; Daly L; DeSombre K; Anselmino L; Hass GM; Berchuck A; Soper JT; Clarke-Pearson DL; Boyer C
J Clin Oncol; 1993 Aug; 11(8):1506-10. PubMed ID: 8336189
[TBL] [Abstract][Full Text] [Related]
17. CA-125 in gynecological malignancies.
Meier W; Stieber P; Fateh-Moghadam A; Eiermann W; Hepp H
Eur J Cancer Clin Oncol; 1987 Jun; 23(6):713-7. PubMed ID: 2443359
[TBL] [Abstract][Full Text] [Related]
18. Pros and cons of gynecologic tumor markers.
Bast RC; Hunter V; Knapp RC
Cancer; 1987 Oct; 60(8 Suppl):1984-92. PubMed ID: 2443235
[TBL] [Abstract][Full Text] [Related]
19. [Rational application of tumor marker CA 125 in gynecological oncology].
Durdević S; Stojanović S; Marijana BN; Maksimović M
Med Pregl; 2010; 63(3-4):195-9. PubMed ID: 21053460
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
